ReviewCancers2025
Fertility Sparing in Endometrial Cancer: Where Are We Now?
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Recurrent Distant Metastatic Endometrial Cancer Treated with Immunotherapy with Pembrolizumab: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Biomaterial-enabled multimodal therapy for endometrial cancer: Subtype-guided immuno-metabolic modulation and fertility-conscious regeneration.Materials today. Bio · 2026Article
- From in-silico QSAR modeling to in-vitro MTT assay: experimental validation of novel uPAR leads for triple-negative breast cancer (TNBC) and skin cancer.Scientific reports · 2026Article
- Persistent endometrial dysfunction after fertility-sparing treatment for endometrial carcinoma: insights from donor oocyte cycles.Frontiers in oncology · 2026Article
- Fertility-Sparing Management of Grade 2 Endometrioid Endometrial Adenocarcinoma Without Progesterone Receptor Expression: A Case Report.Case reports in obstetrics and gynecology · 2026Article
- Molecular Prognosticators Guiding Fertility-Sparing Surgery in Early-Stage Endometrial Cancer: A Comprehensive Review.Cancers · 2025Review
- Epigenetics of Endometrial Cancer: The Role of Chromatin Modifications and Medicolegal Implications.International journal of molecular sciences · 2025Review
- Efficacy of Fertility-Sparing Treatments for Early-Stage Endometrial Cancer-Oncologic and Reproductive Outcomes: Protocol of a Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Article
- Circulating Tumor DNA in Cervical Cancer: Clinical Utility and Medico-Legal Perspectives.Oncology research · 2025Review
- Mapping the relationship between obesity and endometrial cancer: current research hotspots and future trends (2003-2024).Frontiers in oncology · 2025Review
- Application of MRI-guided hysteroscopic one-step resection in preserving the fertility of early endometrial cancer patients.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is the most common gynecological neoplasm with an increased incidence in the premenopausal population in recent decades. This raises the problem of managing endometrial cancer in fertile women who have not yet achieved pregnancy. In these women, after careful selection, hysterectomy may be postponed in favor of conservative management if specific requirements are met. The latest evidence is focused on early endometrial carcinoma, endometrioid histotype, Grading 1, with no evidence of myometrial infiltration. Few clinical trials have opened this possibility also for women with an endometrial cancer Grading 2 diagnosis. There are still questions about the best medical therapy, dosage, route, and duration of treatment. Oral progestins or levonorgestrel-releasing intrauterine devices appear to be the options associated with the best outcome in terms of complete response and lower recurrence rates. Other options include the use of GnRH analogues, surgical hysteroscopy, or metformin, in a therapeutic approach that takes into account the characteristics of the patient. The pursuit of pregnancy should start as soon as two consecutive endometrial biopsies are obtained 3 months apart from each other; it is recommended to refer the patients to ART centers to maximize the success rate. After having reached the fulfillment of the reproductive desire, surgical radical treatment is still recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.